Teva Wins Azilect Patent Dispute Against Mylan - Quick Facts

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced Monday that the U.S. District Court for the District of New Jersey has issued a favorable ruling in the Company's patent infringement lawsuit against Mylan (MYL) regarding an Azilect (rasagiline tablets) patent which covers methods of treating Parkinson's disease or PD. The Court has upheld the validity of Teva's patent.

Teva noted that it anticipates the Court will enter Judgment that prevents Mylan from launching its generic version of Azilect until Teva's patent expires in 2017.

Teva said it filed a lawsuit suit against Mylan in October 2010. Similar lawsuits were filed against Watson and Orchid in October 2010, Apotex in May 2011 and Sandoz in April 2012. Teva reached settlement agreements with Watson, Apotex and Orchid earlier this year. Sandoz has agreed to be bound by a final judgment in the case against Mylan.

Teva noted that it will continue to support the scientific community by further investigating the clinical profile of Azilect and offering important resources, education and financial assistance to patients and physicians through the Parkinson's Support Solutions program.